(Hematuria)
33,516 results
  • Autosomal Dominant Polycystic Kidney Disease Presenting as a Painless Epigastric Mass: A Case Report. [Case Reports]
    Am J Case Rep. 2026 Aug 20; 27:e952751.Zaulkafali TA, Zainal-Abidin ANI, … Mohamed-Yassin MSAJ
  • BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder, typically presenting with hypertension, hematuria, or progressive renal dysfunction. However, it can have a broad range of initial presentations and, in uncommon cases, may mimic other abdominal disorders. This report presents a case of ADPKD manifesting as an epigastric mass in a patient …
  • An Unusual Cause of Hematuria and Flank Pain. [Case Reports]
    Port J Card Thorac Vasc Surg. 2026 Aug 19; 33(2):35-38.Koudounas G, Karkos D, … Karkos CPJ
  • Hematuria and flank pain are a typical urology emergency, often presented as the primary complaint. However, in patients with previous aortolia surgery, these symptoms may rarely indicate external compression of the urinary tract by an anastomotic pseudoaneurysm. We herein describe an unusual case of a 50-year-old man who presented to the urologist with hematuria and right flank pain due to urete…
  • Eosinophilic cystitis refractory to multiple treatments with good response to benralizumab: case report. [Case Reports]
    Front Allergy. 2026; 7:1890965.Ruiz de Galarreta Beristain M, Audicana Berasategui MT, … Uriel Villate OFA
  • CONCLUSIONS: This case demonstrates the efficacy and safety of benralizumab in refractory eosinophilic cystitis, even in the absence of peripheral eosinophilia. Anti-IL-5/IL-5R monoclonal antibodies may represent a valuable steroid-sparing and surgery-sparing therapeutic option for selected patients with refractory disease. Further studies are warranted to confirm these findings and define the role of biologic therapy in this rare condition.
  • Impact of Moses technology on HoLEP day-case success rate: a monocentric matched paired cohort study. [Journal Article]
    World J Urol. 2026 Aug 17; 44(1).Lacroix X, Klein C, … Robert GWJ
  • CONCLUSIONS: In this large propensity-matched cohort of day-case HoLEP, Moses 2.0 technology was safe but did not significantly improve day-case success compared with conventional HoLEP. Although Moses technology enhances intraoperative laser performance, its clinical benefit in an expert outpatient setting appears limited. Further studies should identify subgroups that may derive greater benefit from this technology.